Osteoprotegerin/receptor activator of nuclear factor-kappa B ligand/receptor activator of nuclear factor-kappa B axis in obesity, type 2 diabetes mellitus, and …
ID Vachliotis, SA Polyzos - Current Obesity Reports, 2023 - Springer
Abstract Purpose of Review To summarize evidence on the potential involvement of the
osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (NF-κΒ) ligand …
osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (NF-κΒ) ligand …
Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood
Age‐related changes in human T‐cell populations are important contributors to
immunosenescence. In particular, terminally differentiated CD8+ effector memory CD45RA+ …
immunosenescence. In particular, terminally differentiated CD8+ effector memory CD45RA+ …
Osteokines in Nonalcoholic Fatty Liver Disease
ID Vachliotis, AD Anastasilakis, V Rafailidis… - Current Obesity …, 2024 - Springer
Abstract Purpose of Review To critically summarize evidence on the potential role of
osteokines in the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD) …
osteokines in the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD) …
[HTML][HTML] RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives
F Monti, F Perazza, L Leoni, B Stefanini, S Ferri… - International Journal of …, 2024 - mdpi.com
Metabolic dysfunction-associated steatotic liver disease (MASLD)—and its worse form,
metabolic-associated steatohepatitis (MASH), characterised by inflammation and liver …
metabolic-associated steatohepatitis (MASH), characterised by inflammation and liver …
Association of TNF-α, IGF-1, and IGFBP-1 levels with the severity of osteopenia in mice with nonalcoholic fatty liver disease
TH Wang, JB Li, YG Tian, JX Zheng, XD Li… - Journal of Orthopaedic …, 2023 - Springer
Backgrounds Nonalcoholic fatty liver disease (NAFLD) exhibits a close association with
osteoporosis. This work aims to assess the potential effects of NAFLD on the progression of …
osteoporosis. This work aims to assess the potential effects of NAFLD on the progression of …
Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe
ME Chondrogianni, I Kyrou, T Androutsakos… - Frontiers in …, 2024 - frontiersin.org
Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most
common chronic liver disease globally, affecting 17-38% of the general population and 50 …
common chronic liver disease globally, affecting 17-38% of the general population and 50 …
Osteoprotegerin deficiency aggravates methionine–choline-deficient diet-induced nonalcoholic steatohepatitis in mice
S Wu, Y Wu, L Lin, C Ruan, F Li, R Chen, H Du… - Scientific Reports, 2023 - nature.com
Clinical studies have shown that osteoprotegerin (OPG) is reduced in patients with
nonalcoholic steatohepatitis (NASH), but the underlying mechanisms are unclear. The …
nonalcoholic steatohepatitis (NASH), but the underlying mechanisms are unclear. The …
[PDF][PDF] Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe
T Androutsakos10, CM Flessa, E Menenakos11… - 2024 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD; or metabolic dysfunction-associated fatty liver
disease, MAFLD; or metabolic dysfunction-associated steatotic liver disease, MASLD) is one …
disease, MAFLD; or metabolic dysfunction-associated steatotic liver disease, MASLD) is one …